APLS$20.53
$20.8217
Chart
Performance
Key Stats
AI APLS Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyApellis Pharmaceuticals shows strong fundamental performance with significant revenue growth and robust profitability, supported by a solid balance sheet. However, recent price action indicates potential overvaluation and short-term technical headwinds. The thematic outlook is mixed, with strong product performance but also potential regulatory concerns.
Thematic
Apellis Pharmaceuticals is at the forefront of treating rare diseases, particularly those affecting vision and blood disorders. The company's innovative pipeline and commercial success of its key drugs are significant tailwinds. However, the biopharmaceutical sector is subject to regulatory scrutiny and pricing pressures.
Fundamental
Apellis Pharmaceuticals demonstrates robust financial health, characterized by significant revenue growth and improving profitability. The company maintains a manageable debt level and a healthy cash position, providing flexibility for continued research and development.
Technical
The stock price shows mixed signals. While it is trading above key long-term moving averages, indicating a general upward trend, recent performance suggests volatility and potential short-term overbought conditions. Investors should monitor key support and resistance levels.
| Factor | Score |
|---|---|
| Biopharmaceutical Innovation | 90 |
| Market Penetration & Growth | 95 |
| Regulatory Environment | 40 |
| Disease Specialization | 75 |
| Competition Landscape | 50 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 40 |
| Growth | 95 |
| Balance Sheet Health | 45 |
| Cash Flow | 30 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 60 |
| Volume Confirmation | 50 |
| Support & Resistance | 50 |
| Short-Term Oscillators | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Improved EPS Trend
While EPS has been negative, the reported EPS for Q1 2025 (-0.29) was better than the estimate (-0.39), showing a positive surprise of 24.79%. The company's EPS trend in the last few quarters shows a narrowing of losses compared to estimates. [11]
Potentially Attractive Valuation for Growth
The Price-to-Sales (PS) ratio for TTM is 4.4 and for 2024 is 5.1. While not strictly 'under 1.0', for a biopharmaceutical company, these PS ratios might be considered reasonable if future revenue growth materializes, especially given the potential of their product pipeline. [23]
Bearish Points (8)
Consistent Net Losses
The company has reported net losses for all reported annual periods (2021-2024), with significant net losses in 2022 (-$652.17M) and 2023 (-$528.63M). TTM Net Income is -$186.02M, and the Net Margin is -25.3%. [23, 25, 28]
Negative Earnings, High PS Ratio
The Price-to-Earnings (PE) ratio is negative for all reported periods, indicating a lack of profitability. The Price-to-Sales (PS) ratio, while decreasing from 2021 ($89.3) to 2024 ($5.1), remains significant for a company not yet consistently profitable. [23, 24]
Calendar
July 2025
31
Next Earnings Date
H: $-0.27
A: $-0.48
L: $-0.60
H: 201.84M
A: 187.91M
L: 170.36M
Profile
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Seasonals
Price Target
35.60 USD
The 39 analysts offering 1 year price forecasts for APLS have a max estimate of 60.00 and a min estimate of 17.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Alexion, now part of AstraZeneca, is a leading company in complement inhibition with approved drugs like Soliris and Ultomiris, directly competing with Apellis in complement-mediated rare diseases such as PNH and addressing generalized myasthenia gravis (gMG). [2, 7, 10, 11, 12, 19]
Weight: 95
A major pharmaceutical company identified as a significant rival of Apellis and actively developing complement inhibitors, including small molecule inhibitors of complement factor B. [2, 7, 11, 19]
Weight: 90
Listed as a top competitor of Apellis, Amgen acquired ChemCentryX, which developed a C5aR inhibitor, demonstrating its strategic interest in the complement pathway. [2, 11, 19]
Weight: 90
A significant player in the biotechnology and pharmaceutical sectors with a strong presence in hematology and a pipeline that includes complement inhibitors. Roche also has collaborations related to complement inhibition. [7, 9, 10, 11, 12, 14]